Health PEI
One Island Health System

PEI Pharmacare
P.O. Box 2000
Charlottetown, PE
C1A 7N8
www.healthpei.ca

Santé Î.-P.-É.
Un système de santé unique

Programmes provinciaux de medicaments
C.P. 2000
Charlottetown, PE
C1A 7N8
www.healthpei.ca

# PEI Pharmacare Bulletin

**Issue (2022 - 6)** **June 1, 2022**

## NEW PRODUCT(S) ADDED TO THE PEI PHARMACARE FORMULARY (EFFECTIVE DATE: JUNE 1, 2022)

| Product (Generic name) | Product (Brand name) | Strength | Dosage Form | DIN | MFR |
|---|---|---|---|---|---|
| Glucagon | Baqsimi | 3 mg | Nasal Spray | 02492415 | LIL |
| Criteria | Open benefit for up to 2 devices per 12 months for clients on insulin therapy. For quantities beyond this, a Special Authorization will have to be submitted:<br>• The client will need to meet the following criteria:<br>○ For the treatment of severe hypoglycemia (SH) reactions in patients with diabetes mellitus receiving insulin and at high risk for SH, when impaired consciousness precludes oral carbohydrate administration.<br>• Request should detail the clinical need for greater than 2 glucagon devices per 12 months, including the number of devices anticipated<br>• Request must be from a medical practitioner or nurse practitioner<br>• Special authorization requests for additional doses will be considered for up to one device per month<br>• SA is valid for 12 months<br>• Coverage is limited to one unit at a time | | | | |
| Program Eligibility | Diabetes Drug Program, Financial Assistance Drug Program, Nursing Home Drug Program, Catastrophic Drug Program | | | | |

**Effective June 1, 2022, currently listed Glucagon devices will be eligible in the following manner:**

- Coverage will be in the Diabetes Drug Program, Financial Assistance Drug Program, Nursing Home Drug Program, and Catastrophic Drug program
- The devices will be eligible as a regular benefit for up to two dispenses (one device per dispense) in a 12 month period for clients on insulin therapy
- If more than two devices are required in a 12 month period, a Special Authorization will have to be submitted, and the client meet the following criteria;
  - For the treatment of severe hypoglycemia (SH) reactions in patients with diabetes mellitus receiving insulin and at high risk for SH, when impaired consciousness precludes oral carbohydrate administration.
  - Request should detail the clinical need for greater than 2 glucagon devices per 12 months, including the number of devices anticipated
  - Request must be from a medical practitioner or nurse practitioner
  - Special authorization requests for additional doses will be considered for up to one device per month
  - SA is valid for 12 months
- Coverage is limited to one unit at a time
- The copay in the Diabetes Drug Program will be $20 per device

- In addition to Baqsimi identified above, eligible devices include Glucagon Kit DIN 02243297, Glucagen Kit DIN 02333627, and Glucagen Vial DIN 0233619

**REMINDER: TWO NEW PROGRAMS EFFECTIVE JUNE 1ST:**

- **Substance Use Harm Reduction Drug Program**
  - Please see:
    - "Pharmacist Bulletin - May 2022 (extra)"
    - https://www.princeedwardisland.ca/en/information/health-pei/substance-use-harm-reduction-drug-program

- **Diabetes Glucose Sensor Program**
  - Please see Appendix F in the Formulary for a list of eligible glucose sensor supplies

  - This program is administered by the Provincial Diabetes Program and any questions related to registration, coverage, or billing issues should be directed to:

    Glucose Sensor Program / Insulin Pump Program
    16 Garfield Street
    Charlottetown, PE C1A 6A5
    Telephone: (902) 213-4825 or 1-833-335-0538 (toll free)
    Email: diabetesadminofficer@ihis.org